Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia
Status:
Temporarily Closed
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
NCT#03737981
Eligible for screening study DCP 001
Enrollment to A041702 pre-registration (STEP 0) is temporarily suspended to effective June 14, 2022, at 4:00 PM ET.
